Loading…
CytomX Therapeutics, Inc. is projected to rise to $3.40 by 2027, a +10% move from its current price of $3.10. CTMX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $3.02 | $3.10 | $3.18 | +0.04% |
| Aug 3 | $2.99 | $3.10 | $3.22 | +0.07% |
| Aug 4 | $2.97 | $3.10 | $3.25 | +0.11% |
| Aug 5 | $2.95 | $3.10 | $3.27 | +0.15% |
| Aug 6 | $2.93 | $3.11 | $3.29 | +0.18% |
| Aug 7 | $2.92 | $3.11 | $3.31 | +0.22% |
| Aug 8 | $2.90 | $3.11 | $3.33 | +0.26% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.90 | $3.11 | $3.33 | +0.26% |
| Week 2 | $2.83 | $3.12 | $3.43 | +0.52% |
| Week 3 | $2.78 | $3.12 | $3.52 | +0.78% |
| Week 4 | $2.73 | $3.13 | $3.59 | +1.04% |
| Week 5 | $2.70 | $3.14 | $3.66 | +1.30% |
| Week 6 | $2.66 | $3.15 | $3.72 | +1.56% |
| Week 7 | $2.63 | $3.16 | $3.78 | +1.82% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company that develops potent biologics designed to treat the tumor microenvironment. The company uses conditional activation platform technology for oncology biologics research and development, including validation of targets for antibody-drug conjugates (ADCs), opening therapeutic windows for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators such as cytokines; and PROBODY platform in preclinical research outside of oncology.
It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and a clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab).
The company was founded in 2008 and is based in South San Francisco, California.
CTMX is a biotechnology company focused on oncology, trading at $3.17 per share with a market capitalization of $690.12M and a market rank of 2786. The current price and market position place the stock in a niche biopharma segment with a defined late-stage and preclinical oncology pipeline.
The long-range forecast shows a path of gradual price appreciation, with 2026 averaging around $3.17 and 2050 averaging around $14.43, peaking at $25.29 in the modeled max scenario. Sentiment shifts over time from Neutral in the near term to Bullish in the later years, reflecting expectations of pipeline progression and potential collaborations.
A major floor 24.8% below — a decisive break under it would weaken the trend.
The nearest floor, 4.8% below — buyers have tended to step in here.
The nearest ceiling, 27.6% above — a clean break opens room to run.
A major ceiling 57.7% above — clearing it would confirm fresh momentum.
Key CTMX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CTMX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.20 | Sell | $3.21 | Sell |
| MA 10 | $3.29 | Sell | $3.29 | Sell |
| MA 20 | $3.52 | Sell | $3.39 | Sell |
| MA 50 | $3.40 | Sell | $3.53 | Sell |
| MA 100 | $3.91 | Sell | $3.76 | Sell |
| MA 200 | $4.19 | Sell | $3.73 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 34.78 | Neutral |
| Stoch RSI (14) | 2.36 | Buy |
| CCI (20) | -119.83 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.05 | Sell |
| ROC (12) | -15.76 | Sell |
| Bollinger %B (20,2) | 0.09 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.10 | Sell |
| Awesome (5,34) | -0.22 | Sell |
| Ultimate (7,14,28) | 26.45 | Buy |
| Momentum (10) | -0.52 | Sell |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 3.16 | Sell |
| ADX (14) | 21.76 | Sell |
| ATR (14) | 0.08 | Info |
The 30-day technical picture is BEARISH, with RSI14 at 30. The stock is trading relative to its moving averages, with SMA50 at $3.42 and SMA200 at $4.19. Support is at $2.93 and resistance at $3.95, framing a near-term trading range.
Over the last 30 days, the price has moved within a low of $2.71 and a high of $3.70, indicating a tightening range around the current level as short-term momentum remains limited.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.91 | $3.10 | $4.17 | 0% | Neutral | |
| $2.73 | $3.40 | $4.48 | +10% | Neutral | |
| $2.74 | $3.52 | $4.80 | +13% | Neutral | |
| $2.86 | $3.74 | $5.25 | +21% | Bullish | |
| $2.77 | $3.70 | $5.32 | +19% | Neutral | |
| $3.09 | $4.20 | $6.16 | +36% | Bullish | |
| $3.49 | $4.82 | $7.19 | +55% | Bullish | |
| $3.70 | $5.19 | $7.88 | +68% | Bullish | |
| $4.18 | $5.95 | $9.17 | +92% | Bullish | |
| $4.08 | $5.88 | $9.20 | +90% | Bullish | |
| $5.66 | $8.69 | $14.41 | +180% | Bullish | |
| $8.56 | $14.62 | $26.46 | +372% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.91 | $3.10 | $3.80 | +0.00% |
| September 2026 | $2.67 | $3.15 | $3.82 | +1.56% |
| October 2026 | $2.70 | $3.21 | $3.93 | +1.83% |
| November 2026 | $2.79 | $3.34 | $4.12 | +4.06% |
| December 2026 | $2.79 | $3.35 | $4.17 | +0.45% |
Click any year to see its month-by-month CTMX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, CTMX could reach as high as $4.17, with a base case around $3.10 and support toward $2.91 — roughly 0% from $3.10. A consolidation phase looks the most probable path here.
Expect CTMX to range from $2.73 to $4.48 through 2027. The $3.40 average target implies a +10% move from current prices. That is up +10% on the projected 2026 average. Price action looks broadly range-bound.
The CTMX price prediction for 2028 points to an average of $3.52 (low $2.74, high $4.80) — a potential gain of +13% on today's $3.10. A consolidation phase looks the most probable path here.
In 2029, CTMX is projected to trade between $2.86 and $5.25, averaging $3.74 — a potential gain of +21% from today's $3.10. That is up +7% on the projected 2028 average. Momentum favours further upside here.
CytomX Therapeutics, Inc.'s 2030 outlook centres on $3.70, within a $2.77 to $5.32 range. That is -1% versus the projected 2029 average. That marks a +19% change versus current levels. A consolidation phase looks the most probable path here.
By 2031, CTMX could reach as high as $6.16, with a base case around $4.20 and support toward $3.09 — roughly +36% from $3.10. Momentum favours further upside here.
Expect CTMX to range from $3.49 to $7.19 through 2032. The $4.82 average target implies a +55% move from current prices. That is up +15% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The CTMX price prediction for 2033 points to an average of $5.19 (low $3.70, high $7.88) — a potential gain of +68% on today's $3.10. Momentum favours further upside here.
In 2034, CTMX is projected to trade between $4.18 and $9.17, averaging $5.95 — a potential gain of +92% from today's $3.10. That is up +15% on the projected 2033 average. Buyers look set to stay in control over this stretch.
CytomX Therapeutics, Inc.'s 2035 outlook centres on $5.88, within a $4.08 to $9.20 range. That is -1% versus the projected 2034 average. That marks a +90% change versus current levels. Momentum favours further upside here.
By 2040, CTMX could reach as high as $14.41, with a base case around $8.69 and support toward $5.66 — roughly +180% from $3.10. Buyers look set to stay in control over this stretch.
Expect CTMX to range from $8.56 to $26.46 through 2050. The $14.62 average target implies a +372% move from current prices. That is up +68% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in CTMX today (≈ 322.580645 CTMX) could be worth
$4,716.19
+$3,716.19 (+372%) by 2050 · US Dollar
Based on the average projected CTMX price of $14.62 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CTMXwould be worth at today's price.
$1,000 invested in CTMX on Jul 31, 2025 (≈ 456.620993 CTMX) would be worth
$1,415.53
+$415.53 (+41.6%) today · 1.42× · US Dollar
Based on a CTMX entry price of $2.19 vs. today's $3.1.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.24 | $956.79 | -4.3% |
| 1 month ago | $3.6 | $861.11 | -13.9% |
| 3 months ago | $4.18 | $741.63 | -25.8% |
| 6 months ago | $6.09 | $509.03 | -49.1% |
| 1 year ago | $2.19 | $1,415.53 | +41.6% |
| All time (5.0y) ago | $5.61 | $552.58 | -44.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CTMX forecast.
Our base-case forecast reaches $6.20 around 2040.
Implied market cap at $6.20: $1.35B
The multi-year forecast shows gradual upside with a progression in average prices across years. For 2026, the min is $2.91, the avg is $3.17, and the max is $4.22, with a neutral sentiment. In 2027, the avg rises to $3.47 with a max of $4.52 and a ROI of 9.6, keeping a neutral stance.
In 2028, the avg is $3.59 (max $4.83) and ROI reaches 13.2, remaining Neutral. In 2029, the avg is $3.81 (max $5.26) with ROI 20.1 and a Bullish sentiment. The 2030 forecast shows an avg of $3.79 (max $5.35) with ROI 19.5 and Neutral sentiment.
From 2031 onward, the outlook becomes more bullish: 2031 avg $4.25, max $6.12, ROI 34.2; 2032 avg $4.82, max $7.06, ROI 52.1; 2033 avg $5.21, max $7.74, ROI 64.3; 2034 avg $5.92, max $8.93, ROI 86.9; 2035 avg $5.87, max $8.97, ROI 85.2. The horizon extends to 2040 with avg $8.58, max $13.85, ROI 170.6 and Bullish sentiment.
By 2050, the avg price is projected at $14.43 with a max of $25.29 and ROI of 355.3, continuing a Bullish trajectory. These are estimates, not guarantees, and depend on factors including clinical progress, regulatory outcomes, and market dynamics.
Tap a question to reveal the answer.
The forecast for 2030 shows an avg price of $3.79 with a min of $2.88, a max of $5.35, and a ROI of 19.5. The sentiment for 2030 is Neutral.
Forecasts indicate a path of rising prices with Neutral sentiment through 2030 and Bullish sentiment from 2031 onward. Notably, 2031 shows an avg of $4.25 with ROI 34.2, and 2050 shows an avg of $14.43 with ROI 355.3.
Yes. The 2050 max price is $25.29, and the 2050 avg is $14.43, indicating that prices could exceed $10 over the long term.
Current price is $3.17 and market cap is $690.12M.
The 30-day range is from $2.71 to $3.70.
CytomX Therapeutics, Inc. Community Discussion
0Share your CytomX Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.